The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Novel HER2-targeted combinations in gastric cancer
Yelena Janjigian, MD, Memorial Sloan Kettering Cancer Center, New York, NY, comments on the potential of using the best treatment options upfront for patients with gastric cancer, possibly in combination with newer antibodies. Novel HER2 targeted agents, including HLX-22, which is being investigated for complete HER2 blockade with trastuzumab, are being investigated in this setting. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Ultimately, we’ll have to see the data. But if the data is positive, what you need to understand is that there’s no guarantee that the patient will make it to second or third line. So I think using the best options up front, perhaps even in combination with newer antibodies, will be critical. Of course, there’s HLX-22 also, which is also a very promising HER2 targeted agent looking at complete HER2 blockade with trastuzumab...
Ultimately, we’ll have to see the data. But if the data is positive, what you need to understand is that there’s no guarantee that the patient will make it to second or third line. So I think using the best options up front, perhaps even in combination with newer antibodies, will be critical. Of course, there’s HLX-22 also, which is also a very promising HER2 targeted agent looking at complete HER2 blockade with trastuzumab. So keep an eye on HER2 space and gastric. There’s a lot going on.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
